PubMed Pfaus, J.G., Shadiack, A., Van Soest, T., Tse, M., & Molinoff, P
Acknowledging the growing need for better control of hyperuricemia, considerable research has been dedicated to the discovery and development of innovative therapies designed to meet these clinical challenges
Rather than positioning ibogaine-related opportunities as a standalone commercial focus, the company appears to be evaluating how specialized delivery technologies and intellectual property could complement its existing expertise in metabolic therapeutics and nontraditional administration approaches
The authors found that tirzepatide 15mg was the most efficacious in reducing HbA1c versus placebo (mean difference -2.00%), followed by tirzepatide 10mg (-1.86%) and semaglutide 2.0mg (-1.62%)